Corbus Pharmaceuticals Financials - Benzinga

Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ

Trade with Public

Trade with Public

$11.08

-0.38-3.32%

At close: Sep 4, 5:00 PM EST

$10.99

-0.09-0.81%

After Hours: Sep 4, 6:25 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Corbus Pharmaceuticals Financials

Corbus Pharmaceuticals (CRBP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over losses of $(1.44) per

Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over losses of $(1.39) per

Benzinga Newsdesk

Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Corbus Pharmaceuticals Q4 EPS $(1.25) Beats $(1.38) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.38) by 9.42 percent. This is a 60.26 percent decrease over losses of $(0.78) per share

Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q3 EPS $(1.90) Misses $(1.72) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.72) by 10.72 percent. This is a 65.22 percent decrease over losses of $(1.15) per

Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q2 EPS $(1.44) Beats $(1.52) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.52) by 5.39 percent. This is a 60 percent decrease over losses of $(0.90) per share

Benzinga Newsdesk